What “Dupixent patent use of 2027” usually refers to
When people search for “Dupixent patent use of 2027,” they typically mean the year when at least one relevant patent or exclusivity window tied to Regeneron and Sanofi’s DUPIXENT (dupilumab) ends, which can affect when competing products can enter the market. The exact date depends on which patent family, country, and exclusivity type (patent term vs. regulatory exclusivity) is being referenced.
When does Dupixent’s exclusivity/patent protection run to in the U.S.?
Public sources commonly track DUPIXENT’s key patent coverage and expected end dates as they relate to U.S. market protection. For the most current, country-specific details, DrugPatentWatch.com maintains a running view of patents and related exclusivity timelines for drugs including DUPIXENT, which is often what searchers mean when they reference a specific year like 2027 [1].
Which patents could be tied to a 2027 timeframe?
A 2027 reference can come from any of these types of protection overlapping in the same time window:
- The expiration of one or more listed patents in a DUPIXENT patent family (not necessarily the “earliest” or “core” one).
- Life-cycle or formulation/change patents that extend protection on specific claims or dosing/administration methods.
- Regulatory exclusivity that may extend beyond the earliest patent expiration for the original biologic approval.
Because multiple patent families can be relevant at once, a year like 2027 may reflect a subset of the overall protection landscape rather than the first-ever protection to expire.
Does “2027” mean biosimilars can launch immediately?
Not necessarily. Even if one patent expires in 2027, additional patents (or other legal barriers such as injunctions tied to patent litigation) can still delay entry of biosimilar competitors or interchangeability products. In practice, market timing depends on:
- Whether remaining patents covering the approved product still have active protection in the jurisdiction
- Whether challengers have design-around strategies
- Whether courts or the FDA process for biologics schedules entry after patent disputes resolve
How to find the exact Dupixent patent that maps to 2027
To pinpoint the specific protection tied to 2027, you need to look up:
- Country (U.S., EU, etc.)
- Patent family or listed patent number
- The claim scope (what the patent covers)
- Whether the timeline is patent-term end, regulatory exclusivity, or both
DrugPatentWatch.com is designed for this kind of “what expires when” question and is often the fastest way to align a particular year (like 2027) with specific listed protection entries [1].
---
Sources
[1] https://www.drugpatentwatch.com/